Optimizing Pulmonology Prior Authorizations with Change Healthcare Clearinghouse

The Role of Change Healthcare Clearinghouse in Pulmonology PA

Change Healthcare, an Optum-owned national clearinghouse, is a foundational component for eligibility verification (X12 270/271), claims submission (X12 837), and remittance advice (X12 835). For pulmonology, its role extends to prior authorization submission via X12 278, a critical channel for high-cost therapies and diagnostics. Effective integration ensures that authorization requests for complex respiratory treatments are submitted accurately and efficiently.

High-Volume Pulmonology Prior Authorization Categories

• Asthma biologics, including omalizumab (Xolair), mepolizumab (Nucala), reslizumab (Cinqair), benralizumab (Fasenra), dupilumab (Dupixent), and tezepelumab (Tezspire).
• Home oxygen and BiPAP/CPAP equipment, often overlapping with sleep medicine.
• IPF (idiopathic pulmonary fibrosis) antifibrotics such as pirfenidone (Esbriet) and nintedanib (Ofev).
• Specialty drugs for COPD like ensifentrine (Ohtuvayre) and specific triple-therapy inhalers (Trelegy, Breztri).
• Pulmonary function testing and lung transplant evaluations.

Navigating Complex Clinical Guidelines and Documentation

Pulmonology prior authorizations are heavily guided by clinical standards from bodies like the American Thoracic Society (ATS), Global Initiative for Asthma (GINA), and Global Initiative for Chronic Obstructive Lung Disease (GOLD). For asthma biologics, specific documentation like eosinophil counts, prior controller therapy at maximum dose, and exacerbation history are often required. Non-compliance with these guidelines or missing specific data points is a frequent cause of denial.

Streamlining X12 278 Submissions for Respiratory Therapies

The X12 278 Health Care Services Review transaction is the electronic standard for prior authorization requests. For pulmonology practices, leveraging the Change Healthcare Clearinghouse for X12 278 submissions means a direct electronic pathway to payers. Klivira enhances this by automating the assembly of clinical data from the EMR, ensuring that all required information for high-cost respiratory drugs and equipment is accurately formatted and submitted, reducing manual intervention and potential errors.

Common Pulmonology Prior Authorization Denial Reasons

• Failure to meet payer-specific step therapy requirements for asthma biologics, such as a documented trial of high-dose inhaled corticosteroids (ICS-LABA).
• Eosinophil-count thresholds not being met for IL-5-targeting biologics, as specified by payer policy.
• Insufficient conservative therapy documentation for IPF antifibrotics, indicating a lack of prior treatment attempts.
• Missing or incomplete clinical documentation failing to support medical necessity per ATS, GINA, or GOLD guidelines.

Klivira's Intelligent Automation for Pulmonology Workflows

Klivira integrates directly with your EMR and connects with the Change Healthcare Clearinghouse to automate the entire prior authorization lifecycle for pulmonology. Our platform incorporates GINA, GOLD, and ATS-aware step-therapy logic, streamlines eosinophil-count documentation, and manages complex asthma biologic re-authorization workflows. This ensures that requests are clinically robust and compliant with payer policies, accelerating approvals for critical respiratory care.

Seamless EMR and Payer Touchpoints

Integrating Klivira means your pulmonology practice can leverage existing EMR data to populate prior authorization requests, minimizing data entry. Our connection to the Change Healthcare Clearinghouse facilitates electronic submission to a vast network of payers, ensuring that clinical orders for asthma biologics, home oxygen, or pulmonary rehab flow efficiently from the EMR to the payer, and back with authorization statuses, without manual portal navigation.